A new treatment combination - Keytruda plus Padcev - is now approved for use before and after bladder‑removal surgery, ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, ...

Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the combination of pembrolizumab and enfortumab vedotin for use both before ...

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...

Bladder cancer is a common cancer and one of the most costly to treat, yet there has been little change in the standard of care in 40 years. This panel will focus on the unmet needs in bladder cancer ...

A new study may pave the way toward more personalized treatments for patients with high-risk bladder cancer, according to a study published in European Urology. High-risk non–muscle-invasive bladder ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

A groundbreaking targeted treatment for the most common type of bladder cancer has been approved for use by the NHS, offering new hope to hundreds of patients. The National Institute of Health and ...

Surgery for advanced bladder cancer includes transurethral resection of the bladder tumor (TURBT) to remove tumors and cystectomy to remove all or part of the bladder, with the choice depending on the ...

The National Institute for Health and Care Excellence (NICE) published draft guidance recommending avelumab (Bavencio, Merck Serono) for the treatment of certain forms of bladder cancer. Adults with ...